From: Clinical impact of FDG PET-CT on management decisions for patients with primary biliary tumours
Major | Minor | No impact | ||
---|---|---|---|---|
GB | Initial staging | 33 % (9/27) | 7 % (2/27) | 60 % (16/27) |
Suspected recurrence | 75 % (3/4) | 0 % (0/4) | 25 % (1/4) | |
Total | 39 % (12/31) | 6 % (2/31) | 55 % (17/31) | |
CC intrahepatic | Initial staging | 20 % (9/45) | 11 % (5/45) | 69 % (31/45) |
Suspected recurrence | 56 % (5/9) | 44 % (4/9) | 0 % (0/9) | |
Total | 26 % (14/54) | 17 % (9/54) | 57 % (31/54) | |
CC extrahepatic | Initial staging | 23 % (5/22) | 9 % (2/22) | 68 % (15/22) |
Suspected recurrence | 18 % (2/11) | 64 % (7/11) | 18 % (2/11) | |
Total | 21 % (7/33) | 27 % (9/33) | 52 % (17/33) | |
CC All | Initial staging | 21 % (14/67) | 10 % (7/67) | 69 % (46/67) |
Suspected recurrence | 35 % (7/20) | 55 % (11/20) | 10 % (2/20) | |
Total | 24 % (21/87) | 21 % (18/87) | 55 % (48/87) | |
Total | 28 % (33/118) | 17 % (20/118) | 55 % (65/118) |